Paper Details

  1. Home
  2. Paper Details

Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.

Author: AhmedSairah, AlexanianRaymond, AminiBehrang, BashirQaiser, FengLei, KunacheewaChutima, LeeHans C, ManasanchElisabet E, MehtaRohtesh S, NairRajit, OrlowskiRobert Z, PatelKrina K, QazilbashMuzzaffar H, TabchiSamer, ThomasSheeba K, WeberDonna M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Multiple myeloma (MM) is a type of cancer that often becomes resistant to treatment in later stages. This study reports on the use of a high-dose chemotherapy regimen (mCBAD) in people newly diagnosed with MM, those with MM that has returned or stopped responding to treatment, and those with plasma cell leukemia. This regimen may be used as a bridge to stem cell transplantation or newer treatments.
Paper Details　
Original Abstract of the Article :
Multiple myeloma (MM) usually follows a clinical course leading to refractoriness and limited treatment options in advanced stages, which might need bridge therapies to either autologous stem cell transplantation or novel therapies. We report our experience with the high-dose chemotherapy mCBAD (mod...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/31201134

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma: Navigating the Desert of Cancer Treatment

Multiple myeloma, a type of cancer that affects the bone marrow, is like a desert sandstorm, rapidly consuming the body's vital resources. This study examines the use of a high-dose chemotherapy regimen, mCBAD (modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone), in patients with multiple myeloma and plasma cell leukemia.

The study investigates the effectiveness of this intensive chemotherapy regimen in treating various stages of multiple myeloma, from newly diagnosed to relapsed/refractory cases. It's like seeking a powerful weapon to combat a fierce sandstorm, aiming to eradicate the cancer cells and restore the body's health.

Combatting the Storm: High-Dose Chemotherapy for Multiple Myeloma

The study reports on the use of a high-dose chemotherapy regimen, mCBAD, in patients with multiple myeloma. It's like deploying a well-trained army to fight a powerful sandstorm, aiming to conquer the disease and restore balance. The study examines the effectiveness of this treatment approach in different stages of the disease and explores its potential to provide a bridge to other therapies.

Finding Hope in the Desert: A Quest for Improved Treatment

This study underscores the ongoing search for effective treatments for multiple myeloma, a challenging and often aggressive cancer. It's like recognizing the need to constantly adapt and refine our strategies to combat the ever-changing landscape of cancer. The study encourages further research into new and innovative therapies to improve the lives of patients with multiple myeloma and provide them with a brighter future.

Dr. Camel's Conclusion

This study highlights the challenges and complexities of treating multiple myeloma, a disease that can be both relentless and unpredictable. It's like facing a relentless sandstorm, requiring constant vigilance and adaptability. The study encourages continued research and development of new treatment options to improve the lives of patients with multiple myeloma and give them a fighting chance against this formidable disease.

Date :
  1. Date Completed 2020-08-14
  2. Date Revised 2020-09-01
Further Info :

Pubmed ID

31201134

DOI: Digital Object Identifier

NIHMS1529494

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.